Sievi Capital Oyj
27.1.2021 12:31:44 CET | Globenewswire | Press release
Sievi Capital Plc
Stock exchange release, 27 January 2021 at 1:30 pm EET
A new plan in Sievi Capital’s share-based incentive scheme
Sievi Capital Plc’s Board of Directors has decided on the launch of a new plan as part of the company’s performance-based share scheme.
Sievi Capital’s performance-based share scheme consists of three individual plans starting annually. Each plan includes a three-year performance period that always starts on 1 January as well as the award of shares, if any, at the end of the performance period, provided that the award terms and conditions are fulfilled. The launching of each individual plan requires separate approval from the company’s Board of Directors. Sievi Capital announced the establishment of its performance-based share scheme on 6 March 2020.
The purpose of Sievi Capital’s long-term incentive schemes is to serve as incentive and enhance the commitment of the company’s key personnel and, in this manner, contribute to and align the objectives of the company, its key personnel and its shareholders. The incentive schemes are subject to continued employment in the company: the participant is, as a rule, not entitled to any remuneration under the scheme if the participant’s employment or service relationship with Sievi Capital ends before the share award payment date.
LTI 2021–2023
The Board of Directors has approved the second plan (LTI 2021–2023) under the performance-based share scheme. Its performance period started on 1 January 2021 and the award of shares, if any, will take place in spring 2024, provided that the performance targets for the plan set by the Board of Directors are achieved.
The performance targets applied to the LTI 2021–2023 plan are based on Sievi Capital’s average return on equity (ROE). There are five key persons entitled to participating in the LTI 2021–2023 plan.
If the performance targets set for the LTI 2021–2023 plan are fully achieved, the total number of shares awarded on the basis of the plan is at the maximum approximately 0.3 million Sievi Capital shares (gross; half of this in shares and half in cash, which is used to cover the resulting taxes and tax-like charges). Estimated on the basis of the average share price on 26 January 2021, the trading day preceding this release, the total value of the LTI 2021–2023 plan is approximately EUR 0.4 million.
SIEVI CAPITAL PLC
Board of Directors
FURTHER INFORMATION:
CEO Päivi Marttila, tel. +358 400 285 358
DISTRIBUTION:
Nasdaq Helsinki Ltd
Major media
www.sievicapital.fi
Sievi Capital is a listed (Nasdaq Helsinki) private equity investment company that invests in small and medium-sized Finnish companies. Sievi Capital acts in close partnership with management and co-owners in target companies and actively supports growth, performance and value creation.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN19.9.2026 08:41:28 CEST | Press release
CGTN:CGTN Poll | Why is the SCO Solution for Global Governance Drawing Wide Attention?
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
